Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

August 9th 2021

Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.

Novel Agents Gain Traction in the Treatment of Multiple Myeloma

August 6th 2021

Noa Biran, MD, discusses her predictions for where the field of multiple myeloma is headed as well as some of these agents that have generated excitement for patient populations that are currently an unmet need.

Low-Dose Venetoclax Achieves Promising Results in AL Amyloidosis and Myeloma Subsets

August 5th 2021

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

Dr. Manasanch on Key Takeaways From CASSIOPEIA in Multiple Myeloma

August 3rd 2021

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma

August 3rd 2021

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

Using IMiD-Based Strategies for Relapsed Myeloma

August 3rd 2021

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Dr. Morgan on the Differences in Low- and High-Risk Multiple Myeloma

August 2nd 2021

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

FDA Warns of Increased Risk of Death With Melphalan Flufenamide in Multiple Myeloma

July 29th 2021

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma, has indicated that the doublet resulted in an increased risk of death in this population.

Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple Myeloma

July 28th 2021

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.

Dr. Rosenberg on the Potential Clinical Implications of the GRIFFIN Trial in Multiple Myeloma

July 27th 2021

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

Approaching Treatment of Relapsed/Refractory Myeloma

July 27th 2021

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Role of MRD Assessment in Myeloma

July 27th 2021

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.

Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma

July 20th 2021

Thomas G. Martin, MD, discusses the latest news in frontline, early relapsed, and heavily pretreated multiple myeloma, including the growing promise of quadruplets, emerging targets beyond BCMA, and the potential emergence of quadruplets, venetoclax, and antiviral therapy in amyloidosis.

Improving Maintenance Therapy for Myeloma

July 20th 2021

Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.

High-Risk Multiple Myeloma: Selecting Initial Therapy

July 20th 2021

Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.

Dr. O’Donnell on the Promise of Novel Targets in Multiple Myeloma

July 19th 2021

Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.

COVID-19 Vaccine Fails to Deliver SARS-CoV-2 Spike Antibody Responses in Multiple Myeloma

July 18th 2021

Suboptimal antibody responses to SARS-CoV-2 vaccination have been reported in patients with multiple myeloma, leaving them at a greater risk for developing severe COVID-19.

Developmental Interest in Allogeneic Placenta–Derived Cell Therapies Expands

July 16th 2021

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

Dr. Nadeem on the Uptake of Novel Therapies in Heavily Pretreated Multiple Myeloma

July 15th 2021

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Dr. Kumar on Integrating CAR T-Cell Therapy Into Heavily Pretreated Multiple Myeloma

July 13th 2021

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.